PharmaTelevision - Aisling Capital: Investment Strategies and How to Revive Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Aisling Capital: Investment Strategies and How to Revive Biotech

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dennis Purcell at Aisling Capital. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss:

• Dennis' history in the biotech sector

• Key changes to biotech business models in the last 30 years

• Aisling's investment strategy

• How the company raised US $650M in January 2009, and how that fund is being used

• Investment in IPO

• What needs to change to bring back early-stage investing

• How other investors can work alongside traditional VC's

• Potential opportunities

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Dennis ' history in the biotech sector.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Barcelona at BioEurope. On this show I have Dennis Purcell, who is the Senior Partner and Founder of Aisling Capital, welcome to the show.

Dennis Purcell:

Thanks for having me.

Fintan Walton:

Aisling Capital is something that you've founded but your history and your knowledge with the biotech sector goes back over many years you worked with some of the great names PaineWebber and also with Hambrecht & Quist, what were you doing in those days because that were sort of the hay day of biotech I suppose?

Dennis Purcell:

Yes that was a start when some of the bigger companies really took off, companies like Amgen, and Genentech and Genzyme some of the big companies that have really the bedrock of the industry today, so we took those kinds of companies public for advising on merger transactions in the like so, I worked as a investment banker.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Dennis Purcell

Senior Partner and Founder of Aisling Capital

Mr. Purcell has served as the Senior Managing Partner of Fund I and Fund II since February 2000 and is responsible for the management of the Partnership. Prior to joining Fund I, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, H&Q) for over five years, and served on the Executive Committee of Hambrecht & Quist. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Purcell has also often been cited as one of the sector's leaders. He was honored in the Biotech Hall of Fame by Genetic Engineering News and named to the Biotechnology All-Stars list by Forbes ASAP. Prior to joining H&Q Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. Mr. Purcell currently serves as a director of Dynova Laboratories, Inc. and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals Inc , Auxilium Pharmaceuticals Inc , Cengent Therapeutics Inc and Valentis Inc. He is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO) Emerging Companies Section. He has served as a member of the Advisory Council at Harvard Medical School. Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Aisling Capital

Aisling Capital is a leading private equity fund that invests in products, technologies, and global businesses that advance health. Aisling Capital is led by a group of investment professionals with diverse backgrounds in industry, science, and finance. The team's complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities.